|Articles|July 5, 2023
New FDA Draft Guidance Shows That the Time for Decentralized Clinical Trials is Now.
Author(s)Science 37
On May 1, 2023, the U.S. Food and Drug Administration (FDA) released an updated Draft Guidance on decentralized trials. This release shows that the landscape of clinical research is rapidly evolving. The shift towards decentralized clinical trials presents an exciting opportunity for sponsors to improve patient engagement, enhance data quality, and accelerate clinical research. Are you prepared for what’s to come? Download the insight brief to learn more.
Trending on Applied Clinical Trials Online
1
Syneos Health Expands AI Ecosystem With Three New Platform Partnerships
2
Curavit Acquires Lindus Health Clinical Research Organization Assets to Expand US and European Trial Operations
3
When the Slack Runs Out: AI and the CRO Operating Model
4
ACT Brief: Trial Failures as Administrative Problems, CRO Consolidation for Global Trial Reach, and FDA Approval of First FOP Treatment
5